BioChem, Biovector Therapeutics SA deal

BCHXF’s IAF BioVac Inc. subsidiary (Laval, Quebec) and Biovector will develop nasally administered vaccines for influenza, Neisseria meningitidis and streptococcus

Read the full 207 word article

How to gain access

Continue reading with a
two-week free trial.